Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 8,261 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Risk Clear all
Completed Phase 2 Interventional Results available

Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study

NCT00346398
View directory record Official record
Conditions
Asthma, Allergic Sensitization
Interventions
Oral mucosal immunoprophylaxis (OMIP), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 30 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT01968954
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615;RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Not applicable Interventional

Preventing Obesity in Military Communities, Adolescents

NCT02334202
View directory record Official record
Conditions
Obesity, Weight Gain, Disordered Eating, Eating Disorder
Interventions
Interpersonal Psychotherapy-Weight Gain, Health Education
Behavioral · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
12 Years to 17 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infant-Directed Singing for At-Risk Mothers and Infants

NCT05483153
View directory record Official record
Conditions
Maternal Behavior, Infant Behavior
Interventions
Infant-Directed Singing Coaching
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
3 Months and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Not applicable Interventional Results available

Scenario Tailored Opioid Messaging Program (STOMP) to Improve Risk Understanding in Young Adults

NCT03863353
View directory record Official record
Conditions
Pain, Postoperative, Medication Adherence, Opioid Use, Knowledge, Attitudes, Practice, Risk Reduction Behavior
Interventions
Educational Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
15 Years to 24 Years
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 31, 2026, 11:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Personal Lifestyle Engine (PLX) - Personal Lifestyle Medicine Center (PLMC)

NCT04007939
View directory record Official record
Conditions
Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases, Dental Diseases, Hormone Disturbance, Neurocognitive Dysfunction
Interventions
Not listed
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 31, 2026, 11:07 AM EDT
Completed No phase listed Observational

Prospective Data Analysis of a Quality Improvement Initiative in High Risk Cardiac Surgery Patients

NCT04458701
View directory record Official record
Conditions
Coronary Artery Bypass Graft
Interventions
Hemodynamic monitoring
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

NCT00290511
View directory record Official record
Conditions
Lymphoma
Interventions
Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 31, 2026, 11:07 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Food Genetics Behavior Study

NCT05783765
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Heightened Drive to Eat
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
5 Years to 7 Years
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Parenting Intervention Comparison

NCT01517867
View directory record Official record
Conditions
Behavior Problems, Child
Interventions
Chicago Parent Program, Parent-Child Interaction Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 5 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 31, 2026, 11:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

NCT02792192
View directory record Official record
Conditions
Bladder Cancer
Interventions
Atezolizumab, Bacille Calmette-Guérin
Drug · Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Stanford, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 31, 2026, 11:07 AM EDT
Recruiting Phase 2 Interventional

Horizon Two: HR NDMM (MMRC-100)

NCT07053436
View directory record Official record
Conditions
High Risk Newly Diagnosed Multiple Myeloma
Interventions
Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Carbohydrate Modification in Weight Management Among Obese Children

NCT00215111
View directory record Official record
Conditions
Childhood Obesity
Interventions
Low carbohydrate, reduced glycemic load, and a control diet
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Oct 31, 2026, 11:07 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease

NCT07839871
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 17 Years
Enrollment
920 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
South Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)

NCT01279044
View directory record Official record
Conditions
HIV Infections, Episodic Substance Use
Interventions
Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC), Standard HIV testing with information only
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 31, 2026, 11:07 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

NCT02569398
View directory record Official record
Conditions
Asymptomatic Amyloid-positive
Interventions
Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
557 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth

NCT01910714
View directory record Official record
Conditions
HIV/AIDS
Interventions
Focus On Youth, Health Education Control Condition
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
13 Years to 19 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 31, 2026, 11:07 AM EDT
Terminated Phase 3 Interventional Results available

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

NCT04913675
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Anniston, Alabama • Mesa, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 31, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

NCT00462865
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine and Capecitabine and Avastin
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Albuquerque, New Mexico • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants

NCT00167544
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Encephalomalacia, Premature Birth
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Week to 3 Weeks
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 31, 2026, 11:07 AM EDT
Active, not recruiting Not applicable Interventional

An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.

NCT06660264
View directory record Official record
Conditions
Pharmacogenetics, Pharmacogenomic Drug Interaction
Interventions
Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 11:07 AM EDT
Completed No phase listed Observational

Effectiveness of an Automated Falls-Risk Screening and Referral Tool in the Emergency Department (ED)

NCT05810064
View directory record Official record
Conditions
Falls-Risk
Interventions
Falls-Risk Clinical Decision Support (CDS) Tool
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
65 Years and older
Enrollment
36,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Rockford, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Cerclage On LOw Risk Singletons: Cervical Cerclage for Prevention of Spontaneous Preterm Birth in Low Risk Singleton Pregnancies With Short Cervix

NCT03251729
View directory record Official record
Conditions
Premature Birth
Interventions
Cervical cerclage, Vaginal progesterone
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

NCT01696877
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma in Situ
Interventions
degarelix acetate, Cyclophosphamide, GVAX
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 31, 2026, 11:07 AM EDT